Repurposing Nucleoside Analogs for Human Coronaviruses-Reference-Cited by-同舟云学术

Repurposing Nucleoside Analogs for Human Coronaviruses

Published:2020-12-16 Issue:1 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zandi Keivan¹²,Amblard Franck¹²,Musall Katie¹²,Downs-Bowen Jessica¹²,Kleinbard Ruby¹²,Oo Adrian¹²,Cao Dongdong³,Liang Bo³^ORCID,Russell Olivia O.¹²,McBrayer Tamara¹²,Bassit Leda¹²,Kim Baek¹²,Schinazi Raymond F.¹²^ORCID

Affiliation:

1. Center for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA

2. Children’s Healthcare of Atlanta, Atlanta, Georgia, USA

3. Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA

Abstract

Coronavirus disease 2019 (COVID-19) is a serious illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed confirmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01652-20

Reference36 articles.

1. The Rapid Assessment and Early Warning Models for COVID-19

2. Coronavirus disease 2019 (COVID-19): current status and future perspectives

3. Human and novel coronavirus infections in children: a review